AZTR Azitra Inc AMEX · United States

Azitra (AZTR) news AZTR reverse split and going concern news

Company Updates · Oct 29, 2026

Azitra expands ATR-04 trial to rash from KRAS and MEK inhibitors

Protocol amendments add patients with rash from KRAS and MEK inhibitors, including people with neurofibromatosis type 1, and shorten some washout periods.

Latest Azitra news

Oct 22, 2026Listings
Azitra to carry out 1-for-10 reverse stock split on October 26
Every 10 shares of common stock will combine into one share on NYSE American, with the stock trading on a split-adjusted basis from market open on October 26, 2026.
Oct 1, 2026Company Updates
Azitra advances ATR-04 trial to Cohort 2 after safety review
The safety review committee recommended moving to Cohort 2 after reviewing safety data from Cohort 1. About 24 patients are expected to enroll in the second cohort.
Aug 21, 2026Listings
Azitra regains NYSE American continued listing compliance
NYSE Regulation's August 19, 2026 letter says the company resolved deficiencies under two continued listing standards. A new lapse within 12 months could bring faster action.
Jul 15, 2026Company Updates
Azitra reports ex vivo skin data for its filaggrin cosmetic ingredient
Two ex vivo human skin studies of ATR-COSF showed deeper protein penetration and higher skin elasticity, according to a July 15, 2026 release. A human study is planned next.
Jun 17, 2026Company Updates
Azitra pauses its Netherton trial and moves capital to cosmetics and proteins
In a letter to shareholders issued June 17, 2026, CEO Francisco Salva said the company will redirect funds from ATR-12 enrollment to a filaggrin cosmetic ingredient and recombinant protein work.
Dec 17, 2025Listings
NYSE American accepts Azitra's stockholders' equity compliance plan, sets April 1, 2027 deadline
NYSE American accepted Azitra's plan to restore its $4.0 million minimum stockholders' equity and set April 1, 2027 as the deadline. The stock stays listed while the plan runs, but the company's 2024 annual report carried a going-concern warning.
Oct 3, 2025Listings
Azitra gets NYSE American notice over minimum stockholders' equity requirement
NYSE American told Azitra on October 1, 2025 that its stockholders' equity of $2.2 million is below the $4.0 million required. The company has until October 31, 2025 to submit a plan, with compliance due by April 1, 2027. Its 2024 annual report carried a going-concern warning.
Oct 3, 2025Listings
Azitra gets NYSE American notice over $4 million stockholders' equity standard
NYSE American says Azitra is below its $4 million stockholders' equity standard, and the company has until October 31, 2025 to file a plan to restore compliance.

What Azitra does

Azitra, Inc. is an early-stage clinical biopharmaceutical company developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. Its platform includes a microbial library of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics, augmented by artificial intelligence and machine learning that analyzes and predicts drug-like molecules. The initial focus is genetically engineered strains of Staphylococcus epidermidis. Its lead program, ATR-12, targets Netherton syndrome, a chronic and sometimes fatal skin disease. ATR-04 targets the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy, and received Fast Track designation from the FDA. ATR-01 targets ichthyosis vulgaris, where the company completed lead optimization studies in 2025 and continues IND-enabling studies in 2026. Azitra has partnerships with Carnegie Mellon University, which uses artificial intelligence to mine the library for drug-like peptides and proteins, and with Fred Hutchinson Cancer Center, from which it holds an exclusive worldwide license to the SyMPL technologies. The company says it has not commenced commercial operations.

Product or program	What it is	Stage
ATR-12	Genetically modified S. epidermidis strain for Netherton syndrome	Phase 1b/2a; first patient dosed August 2024
ATR-04	Genetically modified S. epidermidis strain for EGFR inhibitor-associated rash	Phase 1/2; Fast Track designation; first patient dosed in the third quarter of 2025
ATR-01	Engineered strain expressing recombinant human filaggrin for ichthyosis vulgaris	IND-enabling studies in 2026

Summarised from the company's 10-K filed Feb 27, 2026.

Azitra annual financials

Line	FY2025	FY2024
Revenue	$0	$7,500
Research and development	$4.8 million	$4.7 million
Net income (loss)	-$11.0 million	-$9.0 million
Cash from operations	-$11.2 million	-$10.2 million
Cash and equivalents	$2.1 million	$4.6 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $6.7 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Azitra

Did Azitra do a reverse stock split?

Our latest story on this, dated Oct 22, 2026: "Azitra to carry out 1-for-10 reverse stock split on October 26". The story links the filing or release it is based on. Read the story.

Has Azitra issued a going-concern warning?

Our latest story on this, dated Dec 17, 2025: "NYSE American accepts Azitra's stockholders' equity compliance plan, sets April 1, 2027 deadline". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Azitra?

Azitra Inc trades under the ticker AZTR on AMEX.

Where is Azitra listed?

Azitra Inc is listed on AMEX.

What is the SEC CIK of Azitra?

The SEC Central Index Key (CIK) for Azitra Inc is 1701478. Its filings are on SEC EDGAR.

How many shares does Azitra have outstanding?

60,603,742 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is Azitra listed under?

Our directory records Azitra Inc under United States.

What does Azitra do?

Our directory classifies Azitra Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Azitra?

The ISIN recorded for Azitra Inc is US05479L3024.

Does aibio.space cover Azitra?

aibio.space lists Azitra Inc among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Azitra incorporated?

SEC records list its state or country of incorporation as DE.

What does Azitra develop?

What is ATR-12 from Azitra?

ATR-12: Genetically modified S. epidermidis strain for Netherton syndrome Stage: Phase 1b/2a; first patient dosed August 2024.

What is ATR-04 from Azitra?

ATR-04: Genetically modified S. epidermidis strain for EGFR inhibitor-associated rash Stage: Phase 1/2; Fast Track designation; first patient dosed in the third quarter of 2025.

What was Azitra's revenue last year?

$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Investor discussion: Azitra

Members talk about Azitra (AZTR). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Azitra, newest first. Each line links the filing it comes from.

Oct 22, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Aug 21, 2026Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Jun 16, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
May 8, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Apr 27, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Mar 23, 2026Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). Source
Mar 13, 2026Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Feb 6, 2026Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Dec 17, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Oct 3, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Aug 29, 2025Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Aug 20, 2025Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Apr 24, 2025Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Feb 20, 2025Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Jan 14, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Jan 3, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

Press releases

Headlines of Azitra's own announcements, newest first. Each opens the full release on the newswire that carried it.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open AMEX:AZTR on TradingView.

SEC filings and registration

SEC name: Azitra, Inc.
CIK: 1701478
Industry (SIC): Pharmaceutical Preparations (2834)
US tickers: AZTR (NYSE)
State or country of incorporation: DE
Fiscal year ends: December 31
Filer category: <br>Emerging growth company
Business address: 21 BUSINESS PARK DRIVE, SUITE 6, BRANFORD, CT, 06405
Phone: (203) 489-0183
Shares outstanding: 60,603,742 as of 2026-08-11 (10-Q filed 2026-08-12)
Former names: Azitra Inc

Recent filings (8-K and 6-K are the company's own announcements)

8-K filed 2026-10-22
8-K filed 2026-10-01
8-K filed 2026-09-28
424B5 filed 2026-09-28
8-K filed 2026-09-08
8-K filed 2026-08-21
8-K filed 2026-08-12
10-Q filed 2026-08-12

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Azitra Inc is a public biotech or pharmaceutical company listed on AMEX under the ticker AZTR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company: Azitra Inc
Ticker: AZTR
Listing: AMEX
Country or territory: United States
Business scope: Pharmaceuticals: Major
ISIN: US05479L3024
Last quote in directory: 2026-10-13
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction